New Saviour for An Old Problem: Omecamtiv Mecarbil for Systolic Heart Failure

GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 2021; 384: 105–16.

Liu LC , Dorhout B , van der Meer P . Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opin Investig Drugs 2016; 25: 117–27.

FDA grants fast track designation for omecamtiv mecarbil in heart failure [Internet]. Amgen; 8 May 2021 [Accessed 29 January 2021]. Available from: https://www.amgen.com/newsroom/press-releases/2020/05/fda-grants-fast-track-designation-for-omecamtiv-mecarbil-in-heart-failure

Murphy SP , Ibrahim NE , Januzzi JL Jr . Heart failure with reduced ejection fraction: a review. JAMA 2020; 324: 488–504.

Planelles-Herrero VJ , Hartman JJ , Robert-Paganin J . Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun 2017; 8:190.

Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525–33.

Greenberg BH , Chou W , Saikali KG . Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail 2015; 3: 22–29. Erratum in: JACC Heart Fail 2020; 8:700.

COSMIC-HF Investigators. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 2016; 388:2895–903.

ATOMIC-AHF Investigators. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC-AHF study. J Am Coll Cardiol 2016; 67:1444–455.

Corteville DC , Bibbins-Domingo K , Wu AH . N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the heart and soul study. Arch Intern Med 2007; 167: 483–9.

Bauer LA. . Chapter 6. Digoxin. In: Bauer LA. (ed).Applied Clinical Pharmacokinetics [Internet] McGraw-Hill; 2008 [Accessed: 2 February 2021]. Available from: https://accesspharmacy.mhmedical.com/content.aspx?bookid=510&sectionid=40843080

DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 2019; 21:665–75.

ClinicalTrials.gov. Study to assess the effect of omecamtiv mecarbil on exercise capacity in subjects with heart failure (METEORIC-HF). [Internet]. 30 November 2018 [Accessed 2 February 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT03759392